Taro Pharmaceutical Industries (NASDAQ:TARO) says it has received U.S. Food and Drug Administration approval to make and market chewable Teril carbamazepine tablets USP in 200 mg doses.

Teril is Taro's brand name for its carbamazepine products sold in Israel, the U.K. and other countries.

Taro has manufactured carbamazepine products for more than 30 years and is the only company to receive approval for a 200 mg chewable carbamazepine tablet in the U.S.

Carbamazepine is an anticonvulsant widely used in the treatment of epilepsy, and is also indicated for the treatment of trigeminal neuralgia, a painful nerve disorder affecting mostly elderly patients.

According to industry sources, a total of 6.6 million units of carbamazepine products were sold in the U.S. in 2001, of which carbamazepine 100 mg chewable tablets accounted for 1.2 million units.

Taro's carbamazepine products include extended release tablets, immediate release tablets, chewable tablets and liquid suspensions, the company said.

If you liked this article you might like

Nessuah Zannex: Rating cut's main damage is to banks' images to foreigners

Nessuah Zannex: Rating cut's main damage is to banks' images to foreigners

Yes recruitment rate down to 6,000 a month

Yes recruitment rate down to 6,000 a month

Cadence to invest in Israeli startups

Cadence to invest in Israeli startups

Court grants Mentergy 40-day stay of proceedings

Court grants Mentergy 40-day stay of proceedings

Leader & Co sees Discount shifting to profit in Q3

Leader & Co sees Discount shifting to profit in Q3